Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:EYEG

AB Corporate Bond ETF (EYEG) Price, Holdings, & News

AB Corporate Bond ETF logo

About AB Corporate Bond ETF (NASDAQ:EYEG)

Advanced Chart

Key Stats

Today's Range
$34.52
$34.63
50-Day Range
$1.59
$2.25
52-Week Range
$33.92
$37.24
Volume
2,893 shs
Average Volume
1,429 shs
Market Capitalization
$26.37 million
Assets Under Management
$26.34 million
Dividend Yield
5.97%
Net Expense Ratio
0.30%
Aggregate Rating
N/A

ETF Overview

EyeGate Pharmaceuticals, Inc. is a clinical stage specialty pharmaceutical company, which engages in the development and commercialization of products for treating diseases and disorders of the eye. Its pipeline includes MoxiGel and Ocular Bandage Gel. The company was founded in 1998 and is headquartered in Waltham, MA.

AB Corporate Bond ETF Expenses

TypeEYEGInvestment Grade ETFsFixed Income ETFsNASDAQ ETFsAll ETFs
Management Fee0.30%0.23%0.32%0.53%0.53%
Other Expenses0.00%0.12%0.25%0.43%0.52%
Total Expense0.30%0.26%0.39%0.67%0.71%
Fee Waiver0.00%-0.14%-0.25%-0.29%-0.54%
Net Expense0.30%0.24%0.35%0.61%0.60%
Receive EYEG Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for AB Corporate Bond ETF and its competitors with MarketBeat's FREE daily newsletter.

EYEG ETF News Headlines

Warning: “DOGE Collapse” imminent
Elon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week, President Trump promised to buy a Tesla to help support Musk in the face of a boycott against his company. But according to one research group, with connections to the Pentagon and the U.S. government, Elon's preparing to strike back in a much bigger way in the days ahead.
What Economic Factors Influence Corporate Bond Yields?
BUFC AB Conservative Buffer ETF
See More Headlines

EYEG ETF - Frequently Asked Questions

AB Corporate Bond ETF (NASDAQ:EYEG) announced its quarterly earnings results on Thursday, August, 12th. The specialty pharmaceutical company reported ($0.35) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.42) by $0.07.

AB Corporate Bond ETF (EYEG) raised $5 million in an initial public offering (IPO) on Friday, February 13th 2015. The company issued 800,000 shares at $6.00 per share. Aegis Capital Corp and Chardan Capital Markets acted as the underwriters for the IPO.

Top institutional investors of AB Corporate Bond ETF include Wealth Enhancement Advisory Services LLC (12.81%).
View institutional ownership trends
.

Based on aggregate information from My MarketBeat watchlists, some other companies that AB Corporate Bond ETF investors own include Bausch Health Companies (BHC), MannKind (MNKD), Bristol-Myers Squibb (BMY), Sorrento Therapeutics (SRNE), Idera Pharmaceuticals (IDRA), SCYNEXIS (SCYX) and Novavax (NVAX).

Fund Details

Issuer
AllianceBernstein
Fund Name
AB Corporate Bond ETF
Tax Classification
Regulated Investment Company
Stock Exchange
NASDAQ
Current Symbol
NASDAQ:EYEG
Inception Date
12/13/2023
Fund Manager
Timothy Kurpis, Bernd Wuebben

Fund Focus

Asset Class
Fixed Income
Benchmark
N/A
Category
Corporate
Focus
Investment Grade
Development Level
Blended Development
Region
Global
Number of Holdings
460

Fund Statistics

Assets Under Management
$26.34 million
Average Daily Volume
$0.00
Discount/Premium
0.06%

Administrator, Advisor and Custodian

Administrator
State Street Bank and Trust Company
Advisor
AllianceBernstein L.P.
Custodian
State Street Bank and Trust Company
Distributor
Foreside Fund Services, LLC
Transfer Agent
State Street Bank and Trust Company
Trustee
N/A
Lead Market Maker
Jane Street

Options

Optionable
N/A
Short Interest
200 shs

Miscellaneous

Beta
0.16
Creation Unit
50,000
Creation Fee
$250.00
5G Stocks: The Path Forward is Profitable Cover

Enter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

This page (NASDAQ:EYEG) was last updated on 4/26/2025 by MarketBeat.com Staff
From Our Partners